Next Article in Journal
Lipids of Marine Algae—Biomolecules with High Nutritional Value and Important Bioactive Properties
Next Article in Special Issue
Automated—Mechanical Procedure Compared to Gentle Enzymatic Tissue Dissociation in Cell Function Studies
Previous Article in Journal
The Effects of Low-Level Helium–Neon (He–Ne) Laser Irradiation on Lipids and Fatty Acids, and the Activity of Energetic Metabolism Enzymes and Proteome in the Blastula Stage and Underyearlings of the Atlantic Salmon Salmo salar: A Novel Approach in Salmonid Restoration Procedures in the North
Previous Article in Special Issue
Activation of the α1β2γ2L GABAA Receptor by Physiological Agonists
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Biological Evaluation of Benzo[b]thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant Staphylococcus aureus

1
Univ Lyon, INSA Lyon, UCBL, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires, ICBMS, UMR 5246, CNRS, Université Lyon 1, CPE-Lyon, Bâtiment Lederer, 1 Rue Victor Grignard, 69622 Villeurbanne, France
2
Hospices Civils de Lyon, Hôpital de la Croix Rousse-Centre de Biologie Nord, Institut des Agents Infectieux, Laboratoire de Bactériologie, Grande Rue de la Croix Rousse, 69004 Lyon, France
3
Team STAPATH, CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France
4
Centre Commun de RMN, CNRS, Université Lyon 1, CPE-Lyon, Bâtiment Lederer, 1 Rue Victor Grignard, 69622 Villeurbanne, France
*
Author to whom correspondence should be addressed.
Biomolecules 2022, 12(1), 131; https://doi.org/10.3390/biom12010131
Submission received: 14 December 2021 / Revised: 6 January 2022 / Accepted: 10 January 2022 / Published: 14 January 2022
(This article belongs to the Collection Feature Papers in Chemical Biology)

Abstract

:
The benzo[b]thiophene nucleus and the acylhydrazone functional group were combined to prepare three new series of compounds for screening against Staphylococcus aureus. The reaction of substituted benzo[b]thiophene-2-carboxylic hydrazide and various aromatic or heteroaromatic aldehydes led to a collection of 26 final products with extensive structural diversification on the aromatic ring and on position 6 of the benzo[b]thiophene nucleus. The screening lead to the identification of eight hits, including (E)-6-chloro-N’-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (II.b), a non-cytotoxic derivative showing a minimal inhibitory concentration of 4 µg/mL on three S. aureus strains, among which were a reference classical strain and two clinically isolated strains resistant to methicillin and daptomycin, respectively.

1. Introduction

Antimicrobial resistance (AMR) is a public health issue that will continue to worsen in the years to come. At least 700,000 deaths are attributed each year to drug-resistant pathogens, but this could rise to 10,000,000 deaths per year by 2050 [1,2,3]. Among those pathogens, some are widely spread, such as vancomycin-resistant Enterococcus faecium or methicillin-resistant Staphylococcus aureus (MRSA) [4]. The development of new antibiotics targeting antibioresistant bacteria is therefore critical. Substituted benzo[b]thiophenes are interesting compounds in medicinal chemistry [5] that display a broad range of activity including antimicrobial [6,7], anticancer [8], anti-diabetic [9], anti-depressant [10], anti-inflammatory and analgesic agents [11,12]. As part of an ongoing research program aiming at the discovery of new potential antibiotics targeting multidrug-resistant Staphylococcus aureus strains, we combined the benzo[b]thiophene nucleus with the acylhydrazone functional group, which is also relevant in bioactive molecules design [13]. We focused our efforts on the synthesis and biological evaluation of a collection of acylhydrazones built from various aromatic or heteroaromatic aldehydes and benzo[b]thiophene-2-carboxylic hydrazide, readily accessible from benzo[b]thiophene-2-carboxylic acid. This sequence allowed an easy structural diversification of both the heteroaromatic benzo[b]thiophene nucleus and the aromatic system. The purpose was then to screen the collection of benzo[b]thiophene-2-acylhydrazones for identifying new hits against drug-resistant S. aureus strains.

2. Materials and Methods

2.1. Chemistry

2.1.1. General Information

All commercial materials were used as received without further purification. Flash chromatography was carried out using Macherey-Nagel Kieselgel 60 M silica. Analytical thin-layer chromatography was realized using aluminum-backed plates coated with Macherey-Nagel Kieselgel 60 XtraSIL G/UV254 and were visualized under UV light (at 254 nm or 365 nm) or stained using ninhydrin. Nuclear magnetic resonance (NMR) spectra were recorded on Bruker AV300, Bruker AV400 or Bruker AV500 spectrometers, operating at 300 MHz, 400 MHz and 500 MHz, respectively, for the proton (1H) NMR and at 75 MHz, 100 MHz and 125 MHz, respectively, for the carbon (13C) NMR. Chemical shifts were reported in parts per million (ppm) on a scale relative to residual solvent signals. Multiplicities are abbreviated as: s, singlet; d, doublet; t, triplet; q, quadruplets; dd, doublet of doublets; dt, doublet of triplets; td, triplet of doublets; ddd, doublet of doublet of doublets; m, multiplet. Coupling constants were measured in Hertz (Hz). Copies of NMR spectra of new products are available in Supplementary Materials (Figure S1). High-resolution mass spectra (HRMS) and low-resolution mass spectra were obtained by the Centre Commun de Spectrométrie de Masse (CCSM), University of Lyon 1, Lyon, France. LogP calculations were performed using Molinspiration Cheminformatics free web services, https://www.molinspiration.com (accessed on 13 January 2022), Slovensky Grob, Slovakia.

2.1.2. General Procedure for Ethyl 6-halogenobenzo[b]thiophene-2-carboxylate (4)

Under a dried and inert atmosphere (N2), a solution of 4-chloro-2-fluorobenzaldehyde (14.9 mmol, 1 eq.), ethyl thioglycolate (16.5 mmol, 1.1 eq.) and triethylamine (45 mmol, 3 eq.) in anhydrous DMSO (20 mL) was stirred at 80 °C for 2 h and at room temperature overnight. The mix was then poured into 800 mL of ice/water and stirred vigorously. After 1 h of digestion, the formed solid was filtered, washed with water, and dried by suction. (Adapted from Fedi et al. 2007 [14])

Ethyl 6-chlorobenzo[b]thiophene-2-carboxylate (4a)

Yellow crystals (3.446 g, 96% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.25 (d, J = 2.0 Hz, 1H), 8.21 (s, 1H), 8.04 (d, J = 8.6 Hz, 1H), 7.52 (dd, J = 8.6, 2.0 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). (Spectrum in accordance with patent WO2018/122232 [15]).

Ethyl 6-fluorobenzo[b]thiophene-2-carboxylate (4b)

No crystallization occurred in water, and the residue was purified by chromatography (eluent: pentane/Et2O 10:1). White powder (710 mg, 21% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 8.07 (dd, J = 9.1, 5.4 Hz, 1H), 7.99 (dd, J = 9.1, 2.4 Hz, 1H), 7.37 (td, J = 9.1, 2.4 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). (Spectrum in accordance with Cheng et al. [16]).

2.1.3. Procedure for Ethyl 6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate (4c)

Under a dried and inert atmosphere (N2), a solution of 2-fluoro-4-(trifluoromethyl)benzaldehyde (5.20 mmol, 1 eq.), ethyl thioglycolate (6.20 mmol, 1.2 eq.) and K2CO3 (5.70 mmol, 1.1 eq.) in anhydrous DMF (10 mL) was stirred at 60 °C for 2 h. The mix was then diluted with water (20 mL), extracted with Et2O, dried over Na2SO4 and concentrated under vacuum. The residue was then recrystallized in MeOH and filtered. (Adapted from patent WO2018/122232 [15]).

Ethyl 6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate (4c)

White powder (814 mg, 57% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.16 (q, J = 0.8 Hz, 1H), 8.10 (d, J = 0.8 Hz, 1H), 7.98 (dt, J = 8.4, 0.8 Hz, 1H), 7.63 (dd, J = 8.4, 1.6 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H). (Spectrum in accordance with Tan et al. [17]).

2.1.4. Procedure for Ethyl 6-chlorobenzofuran-2-carboxylate (4d)

A solution of 4-chlorosalicylaldehyde (6.39 mmol, 1 eq.), ethyl bromomalonate (13.03 mmol, 2.04 eq.) and K2CO3 (19.74 mmol, 3.09 eq.) in 2-butanone (6 mL) was stirred at 90 °C for 7 h, then at room temperature for 18 h. The mixture was then diluted with EtOAc, neutralized with HCl 1 N and extracted. The organic phase was washed with saturated NaHCO3 and brine, dried over Na2SO4 and concentrated under vacuum. The residue was then purified by chromatography (eluent: pentane/Et2O 9:1). (Adapted from Patent US2015315198 [18]).

Ethyl 6-chlorobenzofuran-2-carboxylate (4d)

White powder (611 mg, 43% yield). 1H NMR (300 MHz, Chloroform-d) δ 7.62–7.57 (m, 2H), 7.49 (d, J = 1.3 Hz, 1H), 7.29 (dd, J = 8.5, 1.3 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H). (Spectrum in accordance with Chen et al. 2017 [19]).

2.1.5. General Procedure for Benzo[b]thiophene-2-carboxylic Acids (1)

To a solution of ethyl 6-chlorobenzo[b]thiophene-2-carboxylate (14.1 mmol, 1 eq.) in EtOH (15 mL) was added a solution of NaOH 3N (28.2 mmol, 2 eq.). The solution was stirred at room temperature overnight, concentrated under vacuum, diluted with H2O (75 mL), acidified with HCl 1 N, extracted with EtOAc, dried over Na2SO4 and concentrated under vacuum. (Adapted from Patent WO2018/122232 [15]).

6-Chlorobenzo[b]thiophene-2-carboxylic acid (1b)

White powder (2.616 g, 87% yield). 1H NMR (300 MHz, DMSO-d6) δ 13.57 (bs, 1H), 8.23 (d, J = 2.0 Hz, 1H), 8.12 (s, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 8.6, 2.0 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 163.48, 142.6, 137.59, 135.82, 132.07, 129.89, 127.20, 125.84, 122.60.

6-Fluorobenzo[b]thiophene-2-carboxylic acid (1c)

Yellowish powder (295 mg, 75% yield). 1H NMR (300 MHz, DMSO-d6) δ 13.46 (s, 1H), 8.12 (d, J = 0.8 Hz, 1H), 8.05 (dd, J = 9.0, 5.4 Hz, 1H), 7.98 (dd, J = 9.4, 2.6 Hz, 1H), 7.35 (td, J = 9.0, 2.6 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 163.48 161.43 (d, J = 245.2 Hz), 142.76 (d, J = 11.3 Hz), 135.75, 134.96 (d, J = 3.9 Hz), 129.99, 127.70 (d, J = 9.6 Hz), 114.48 (d, J = 24.8 Hz), 109.13 (d, J = 26.2 Hz). (Spectrum in accordance with Cai et al. [20]).

6-(Trifluoromethyl)benzo[b]thiophene-2-carboxylic acid (1d)

White powder (400 mg, 89% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.59 (q, J = 0.8 Hz, 1H), 8.10 (d, J = 0.8 Hz, 1H), 7.98 (dt, J = 8.5, 0.8 Hz, 1H), 7.75 (dd, J = 8.5, 1.3 Hz, 1H). (Spectrum in accordance with Tan et al. [17]).

6-Chlorobenzofuran-2-carboxylic acid (1e)

White powder (378 mg, 86% yield). 1H NMR (300 MHz, DMSO-d6) δ 7.90 (d, J = 1.9 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 1.0 Hz, 1H), 7.40 (dd, J = 8.4, 1.9 Hz, 1H). (Spectrum in accordance with Gensini et al. [21]).

2.1.6. General Procedure for Tert-butyl 2-(benzo[b]thiophene-2-carbonyl)hydrazine-1-carboxylates (2)

Under a dried and inert atmosphere (N2), a solution of benzothiophene-2-carboxylic acid (11 mmol, 1.1 eq.) and tert-butyl carbazate (10 mmol, 1.0 eq.) in anhydrous DCM (40 mL) was cooled to 0 °C. Then, DMAP (1.3 mmol, 0.13 eq.) was added to the mixture. DCC (12 mmol, 1.2 eq.) in anhydrous DCM (10 mL) was added dropwise. The mixture was then stirred at room temperature for 24 h, filtered on Celite® and washed with DCM. The filtrate was then concentrated, and the viscous yellow oil was purified by chromatography (eluent: pentane/Et2O, 1:1).

Tert-butyl-2-(benzo[b]thiophene-2-carbonyl)hydrazine-1-carboxylate (2a)

White powder (2.630 g, 88% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.77 (s, 1H), 7.83 (s, 1H), 7.75 (t, J = 6.9 Hz, 2H), 7.47–7.31 (m, 2H), 6.82 (s, 1H), 1.50 (s, 9H); 13C NMR (75 MHz, Chloroform-d) δ 162.4, 156.2, 141.1, 138.9, 135.3, 126.6, 126.5, 125.4, 124.8, 122.4, 82.3, 28.1.

Tert-butyl-2-(6-chlorobenzo[b]thiophene-2-carbonyl)hydrazine-1-carboxylate (2b)

Acid 1b was used. White powder (1.435 g, 79% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.73 (s, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.33 (dd, J = 8.6, 1.9 Hz, 1H), 6.72 (s, 1H), 1.51 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 162.42, 156.46, 142.96, 139.20, 138.93, 132.97, 127.41, 126.55, 125.83, 123.03, 80.78, 28.39.

Tert-butyl-2-(6-fluorobenzo[b]thiophene-2-carbonyl)hydrazine-1-carboxylate (2c)

Acid 1c was used. White powder (305 mg, 42% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.41 (s, 1H), 7.79 (s, 1H), 7.75 (dd, J = 8.9, 5.2 Hz, 1H), 7.45 (d, J = 8.9 Hz, 1H), 7.14 (td, J = 8.9, 2.4 Hz, 1H), 6.67 (s, 1H), 1.51 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 162.19, 160.52 (d, J = 153.3 Hz), 155.39, 141.54 (d, J = 10.8 Hz), 137.52 (d, J = 3.0 Hz), 135.91, 127.24 (d, J = 9.4 Hz), 125.14, 114.27 (d, J = 24.4 Hz), 108.98 (d, J = 26.2 Hz), 79.49, 28.08.

Tert-butyl-2-(6-(trifluoromethyl)benzo[b]thiophene-2-carbonyl)hydrazine-1-carboxylate (2d)

Acid 1d was used. White powder (213 mg, 64% yield). 1H NMR (300 MHz, Chloroform-d) δ 9.11 (s, 1H), 7.94 (s, 1H), 7.82 (d, J = 8.7 Hz, 1H), 7.80 (s, 1H), 7.56 (dd, J = 8.7, 1.7 Hz, 1H), 6.76 (s, 1H), 1.53 (s, 9H); 13C NMR (75 MHz, Acetone-d6) δ 162.23, 156.45, 142.86, 142.07, 141.57, 128.48 (q, J = 32.3 Hz), 127.07, 125.77, 125.4 (q, J = 271.5 Hz), 122.16 (q, J = 3.5 Hz), 121.22 (q, J = 4.5 Hz), 80.88, 28.40.

Tert-butyl-2-(6-chlorobenzofuran-2-carbonyl)hydrazine-1-carboxylate (2e)

Acid 1e was used. White powder (281 mg, 78% yield). 1H NMR (300 MHz, Acetone-d6) δ 9.74 (s, 1H), 8.17 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.65–7.53 (m, 2H), 7.35 (dd, J = 8.4, 1.8 Hz, 1H), 1.45 (s, 9H); 13C NMR (75 MHz, Acetone-d6) δ 158.77, 156.30, 155.75, 149.81, 133.17, 127.08, 125.38, 124.68, 112.96, 111.27, 80.77, 28.39.

2.1.7. General Procedure for N-Acylhydrazones Derivatives (I, II and III)

Step 1: A solution of tert-butyl 2-(benzo[b]thiophene-2-carbonyl)hydrazine-1-carboxylate (1 mmol, 1 eq.) and TFA (20 mmol, 20 eq.) in anhydrous DCM (3 mL) was stirred at room temperature for 18 h. The mixture was co-evaporated with toluene to produce a white solid, which was engaged as crude material in the next step.
Step 2: The crude material was diluted in MeOH (10 mL) before the addition of the corresponding substituted benzaldehyde (2 mmol, 2 eq.) at room temperature. Reflux for 2 h was performed, and the final compound crystallized from the reaction mixture. Then, the reaction mixture was cooled to 0 °C, and the solid was filtered off and washed with cold MeOH.

(E)-N’-(Benzo[d][1,3]dioxol-5-ylmethylene)benzo[b]thiophene-2-carbohydrazide (I.a)

Light-yellow solid (127 mg, 52% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.05 (s, 0.5H), 11.94 (s, 0.5H), 8.40 (d, J = 7.6 Hz, 1H), 8.23 (s, 0.5H), 8.16–7.97 (m, 2.5H), 7.69–7.37 (m, 2.5H), 7.32 (s, 0.5H), 7.28–7.18 (m, 1H), 7.03 (t, J = 7.1 Hz, 1H), 6.13 (s, 1H), 6.11 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 161.9, 158.5, 149.7, 149.6, 148.5, 148.4, 145.0, 143.5, 140.8, 139.5, 138.9, 137.7, 133.7, 132.3, 129.0, 128.8, 127.2, 127.0, 126.0, 125.8, 125.5, 125.2, 124.2, 124.0, 123.3, 123.1, 109.1, 109.0, 106.0, 105.7, 102.1; HRMS (ESI) m/z: calcd. for C17H13N2O3S [M + H]+ 325.0641, found 325.0641.

(E)-N’-(4-(Dimethylamino)benzylidene)benzo[b]thiophene-2-carbohydrazide (I.b)

Yellow solid (99 mg, 45% yield). 1H NMR (300 MHz, DMSO-d6) δ 11.85 (s, 0.5H), 11.78 (s, 0.5H), 8.40 (s, 0.5H), 8.32 (s, 0.5H), 8.20 (s, 0.5H), 8.13–7.94 (m, 2.5H), 7.68 (d, J = 8.7 Hz, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.52–7.41 (m, 2H), 6.82 (d, J = 8.7 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 3.00 (s, 3H), 2.99 (s, 3H); MS (ESI) m/z = 324.1 [M + H]+, 346.1 [M + Na]+.

(E)-N’-(Pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (I.c)

Intermediate 2a (938 mg) was deprotected under the reported acidic conditions (TFA) to produce, after an aqueous workup with NaHCO3 and extractions with EtOAc, a white solid (615 mg), which was directly engaged in the presence of 2-pyridinecarboxaldehyde (6.40 mmol, 2.0 eq.) in MeOH (20 mL). After 2 h reflux, the reaction mixture was concentrated in vacuo to give a brown viscous oil, which was purified by recrystallization in EtOAc to give product. White powder (292 mg, 32% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.34 (s, 1H, 0.5H), 12.26 (s, 0.5H), 8.65 (d, J = 4.5 Hz, 1H), 8.49 (d, J = 10.6 Hz, 1H), 8.29 (s, 0.5H), 8.23 (s, 1H), 8.16–7.85 (m, 3.5H), 7.61–7.37 (m, 3H); 13C NMR (100 MHz, DMSO-d6) δ 162.3, 158.9, 153.5, 153.4, 150.1, 148.7, 145.6, 143.4, 140.9, 139.5, 138.4, 137.8, 137.6, 137.4, 133.5, 132.6, 127.3, 127.2, 126.6, 126.1, 126.0, 125.6, 125.3, 125.0, 123.3, 123.1, 120.8, 120.5; HRMS (ESI) m/z: calcd. for C15H12N3OS [M + H]+ 282.0696, found 282.0682.

(E)-N’-(Pyridin-3-ylmethylene)benzo[b]thiophene-2-carbohydrazide (I.d)

White powder (129 mg, 67% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.32 (s, 0.5H), 12.21 (s, 0.5H), 8.99 (s, 0.5H), 8.89 (s, 0.5H), 8.74–8.60 (m, 1H), 8.52 (s, 0.5H), 8.44 (s, 0.5H), 8.27 (s, 1H), 8.24–8.14 (m, 1H), 8.13–7.98 (m, 2H), 7.59–7.39 (m, 3H); 13C NMR (126 MHz, DMSO-d6) δ 161.86, 161.44, 158.42, 150.89, 150.69, 148.91, 145.43, 143.10, 142.06, 140.49, 140.39, 139.08, 138.09, 137.36, 137.10, 134.08, 133.62, 132.15, 130.14, 130.06, 126.87, 126.73, 126.11, 126.03, 125.69, 125.55, 125.20, 124.90, 124.11, 122.92, 122.67; HRMS (ESI) m/z: calcd. for C15H12N3OS [M + H]+ 282.0696, found 282.0694.

(E)-N’-(Pyridin-4-ylmethylene)benzo[b]thiophene-2-carbohydrazide (I.e)

Crystallized very slowly in the reaction mixture after the reflux. The mixture was concentrated and then engaged in recrystallization with MeOH and EtOAc. Light-yellow powder (92 mg, 30% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.41 (s, 0.5H), 12.32 (s, 0.5H), 8.70 (s, 2H), 8.46 (s, 1H), 8.29 (s, 0.5H), 8.20–7.98 (m, 2.5H), 7.80 z(s, 1H), 7.71 (s, 1H), 7.58–7.43 (m, 2H); MS (ESI) m/z = 282.0 [M + H]+, 304.0 [M + Na]+.

(E)-N’-(3-Hydroxybenzylidene)benzo[b]thiophene-2-carbohydrazide (I.f)

Did not crystallize in the reaction mixture after the reflux. The mixture was concentrated and then engaged in recrystallization with MeOH and EtOAc (8:2). Light-brown powder (47 mg, 27% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.10 (s, 0.5H), 11.99 (s, 0.5H), 9.75 (s, 0.5H), 9.67 (s, 0.5H), 8.41 (d, J = 11.2 Hz, 1H), 8.25 (s, 0.5H), 8.14–7.95 (m, 2.5H), 7.57–7.44 (m, 2H), 7.38–7.21 (m, 2.5H), 7.14 (d, J = 7.7 Hz, 0.5H), 6.88 (s, 1H); MS (ESI) m/z = 297.1 [M + H]+, 319.0 [M + Na]+.

(E)-N’-(4-Hydroxybenzylidene)benzo[b]thiophene-2-carbohydrazide (I.g)

White powder (32 mg, 10% yield). 1H NMR (300 MHz, DMSO-d6) δ 11.95 (s, 0.5H), 11.85 (s, 0.5H), 10.00 (s, 0.5H), 9.97 (s, 0.5H), 8.41 (s, 0.5H), 8.36 (s, 0.5H), 8.22 (s, 0.5H), 8.11–7.96 (m, 2.5H), 7.69 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.55–7.39 (m, 2H), 6.90 (d, J = 8.3 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H); MS (ESI) m/z = 297.1 [M + H]+, 319.0 [M + Na]+.

(E)-N’-(4-Hydroxy-3-methoxybenzylidene)benzo[b]thiophene-2-carbohydrazide (I.h)

White powder (141 mg, 41% yield). 1H NMR (300 MHz, DMSO-d6) δ 11.97 (s, 0.5H), 11.93 (s, 0.5H), 9.62 (s, 0.5H), 9.60 (s, 0.5H), 8.42 (s, 0.5H), 8.36 (s, 0.5H), 8.22 (s, 0.5H), 8.10–7.96 (m, 2.5H), 7.58–7.41 (m, 2.5H), 7.33 (s, 0.5H), 7.20 (d, J = 8.2 Hz, 0.5H), 7.13 (d, J = 8.2 Hz, 0.5H), 6.87 (t, J = 7.2 Hz, 1H), 3.92 (s, 1.5H), 3.84 (s, 1.5H); MS (ESI) m/z = 327.1 [M + H]+, 349.0 [M + Na]+.

(E)-N’-(4-Chlorobenzylidene)benzo[b]thiophene-2-carbohydrazide (I.i)

White solid (216 mg, 62% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.22 (s, 0.5H), 12.10 (s, 0.5H), 8.44 (d, J = 11.4 Hz, 1H), 8.26 (s, 0.5H), 8.16 (s, 0.5H), 8.10–7.97 (m, 2H), 7.88 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.63–7.39 (m, 4H); MS (ESI) m/z = 315.0 [M + H]+, 337.0 [M + Na]+.

(E)-N’-(4-Fluorobenzylidene)benzo[b]thiophene-2-carbohydrazide (I.j)

White solid (173 mg, 44% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.17 (s, 0.5H), 12.06 (s, 0.5H), 8.45 (d, J = 14.0 Hz, 1H), 8.25 (s, 0.5H), 8.17 (s, 0.5H), 8.13–7.99 (m, 2H), 7.92 (t, J = 6.8 Hz, 1H), 7.83 (t, J = 6.8 Hz, 1H), 7.56–7.42 (m, 2H), 7.40–7.27 (m, 2H); MS (ESI) m/z = 299.1 [M + H]+, 321.0 [M + Na]+.

(E)-N’-(3-Nitrobenzylidene)benzo[b]thiophene-2-carbohydrazide (I.k)

Yellowish solid (111 mg, 36% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.41 (s, 0.5H), 12.30 (s, 0.5H), 8.68 (s, 0.5H), 8.58 (s, 1H), 8.44 (s, 0.5H), 8.36–8.16 (m, 3H), 8.05 (s, 2H), 7.87–7.68 (m, 1H), 7.58–7.41 (m, 2H); MS (ESI) m/z = 326.1 [M + H]+, 348.0 [M + Na]+.

(E)-N’-(4-Nitrobenzylidene)benzo[b]thiophene-2-carbohydrazide (I.l)

Yellowish solid (110 mg, 30% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.43 (s, 0.5H), 12.35 (s, 0.5H), 8.56 (s, 0.5H), 8.44 (s, 0.5H), 8.33 (d, J = 8.4 Hz, 3H), 8.18–7.94 (m, 4H), 7.59–7.39 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 161.98, 158.47, 147.90, 145.52, 142.41, 140.44, 138.97, 137.85, 137.34, 132.22, 128.35, 128.14, 126.25, 125.58, 125.18, 124.91, 124.12, 122.89, 122.71; HRMS (ESI) m/z: calcd. for C16H10N3O3S [M − H] 324.0448, found 324.0449.

(E)-2-((2-(Benzo[b]thiophene-2-carbonyl)hydrazono)methyl)benzoic acid (I.m)

White solid (88 mg, 45% yield). 1H NMR (300 MHz, DMSO-d6) δ 13.40 (s, 1H), 12.37 (s, 0.5H), 12.18 (s, 0.5H), 9.23 (s, 0.5H), 8.94 (s, 0.5H), 8.42 (s, 0.5H), 8.32 (s, 0.5H), 8.28–7.97 (m, 3H), 7.93 (dd, J = 7.7, 1.4 Hz, 1H), 7.81–7.61 (m, 1H), 7.61–7.42 (m, 3H); MS (ESI) m/z = 325.1 [M + H]+, 347.0 [M + Na]+.

(E)-3-((2-(Benzo[b]thiophene-2-carbonyl)hydrazineylidene)methyl)benzoic acid (I.n)

White powder (188 mg, 85% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.29 (s, 0.5H), 12.16 (s, 0.5H), 8.52 (s, 0.5H), 8.49–8.30 (m, 1.5H), 8.32–7.91 (m, 5H), 7.71–7.57 (m, 1H), 7.57–7.41 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 166.97, 161.82, 161.41, 158.41, 147.15, 143.87, 143.00, 140.46, 139.08, 138.17, 137.40, 134.68, 132.01, 131.65, 131.51, 131.11, 130.78, 129.36, 128.54, 127.54, 126.91, 126.72, 125.97, 125.56, 125.20, 124.96, 122.93, 122.49; HRMS (ESI) m/z: calcd. for C17H13N2O3S [M + H]+ 325.0641, found 325.0626.

(E)-4-((2-(Benzo[b]thiophene-2-carbonyl)hydrazono)methyl)benzoic acid (I.o)

White solid (92 mg, 39% yield). 1H NMR (300 MHz, DMSO-d6) δ 13.14 (s, 1H), 12.30 (s, 0.5H), 12.19 (s, 0.5H), 8.53 (s, 0.5H), 8.44 (s, 0.5H), 8.28 (s, 0.5H), 8.23 (s, 0.5H), 8.13–7.81 (m, 6H), 7.57–7.40 (m, 2H); MS (ESI) m/z = 325.1 [M + H]+, 347.0 [M + Na]+.

(E)-N’-(Benzo[d][1,3]dioxol-5-ylmethylene)-6-chlorobenzo[b]thiophene-2-carbohydrazide (II.a)

Intermediate 2b was deprotected under the reported acidic conditions (TFA) to afford a white solid, which was engaged without further purification for the next step. White powder (75 mg, 31% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.08 (s, 0.5H), 11.97 (s, 0.5H), 8.39 (d, J = 8.3 Hz, 1H), 8.33–7.97 (m, 3H), 7.48 (d, J = 9.3 Hz, 1.5H), 7.31 (s, 0.5H), 7.23 (t, J = 9.9 Hz, 1H), 7.10–6.97 (m, 1H), 6.13 (s, 1H), 6.11 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 161.18, 157.85, 149.26, 148.16, 144.90, 144.40, 141.58, 139.44, 137.86, 136.02, 134.19, 131.37, 128.52, 128.28, 127.01, 126.83, 125.77, 125.48, 125.07, 123.96, 123.67, 122.48, 122.24, 108.65, 105.64, 105.27, 101.68; HRMS (ESI) m/z: calcd. for C17H12ClN2O3S [M + H]+ 359.0252, found 359.0254.

(E)-6-Chloro-N’-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (II.b)

Intermediate 2b was deprotected under the reported acidic conditions (TFA) to afford, after an aqueous workup with NaHCO3 and extractions with EtOAc, a white solid, which was engaged without further purification for the next step. White solid (52 mg, 30% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.08 (s, 0.5H), 11.97 (s, 0.5H), 8.39 (d, J = 8.3 Hz, 1H), 8.33–7.97 (m, 3H), 7.48 (d, J = 9.3 Hz, 1.5H), 7.31 (s, 0.5H), 7.23 (t, J = 9.9 Hz, 1H), 7.10–6.97 (m, 1H), 6.13 (s, 1H), 6.11 (s, 1H); 13C NMR (126 MHz, DMSO-d6) δ 161.52, 158.24, 153.04, 152.82, 149.69, 148.52, 145.41, 144.33, 141.70, 138.90, 137.81, 137.07, 136.13, 133.96, 131.69, 127.20, 126.99, 125.88, 125.68, 125.58, 124.63, 122.54, 122.24, 120.51, 120.16; HRMS (ESI) m/z: calcd. for C15H11ClN3OS [M + H]+ 316.0306, found 316.0315

(E)-N’-(Benzo[d][1,3]dioxol-5-ylmethylene)-6-fluorobenzo[b]thiophene-2-carbohydrazide (II.c)

Intermediate 2c was deprotected under the reported acidic conditions (TFA) to afford a white solid, which was engaged without further purification for the next step. White powder (44 mg, 40% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.05 (s, 0.5H), 11.93 (s, 0.5H), 8.38 (d, J = 8.7 Hz, 1H), 8.21 (s, 0.5H), 8.16–7.89 (m, 2.5H), 7.46 (s, 0.5H), 7.41–7.28 (m, 1.5H), 7.23 (t, J = 8.9 Hz, 1H), 7.11–6.92 (m, 1H), 6.13 (s, 1H), 6.11 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 157.89, 149.33, 149.24, 148.14, 148.08, 148.06, 148.01, 144.80, 138.58, 138.55, 135.97, 134.17, 133.40, 131.45, 128.56, 128.31, 127.48, 125.09, 123.92, 123.62, 114.20, 109.15, 108.73, 108.63, 108.56, 108.49, 105.57, 105.26, 101.67; HRMS (ESI) m/z: calcd. for C17H12FN2O3S [M + H]+ 343.0547, found 343.0550.

(E)-6-Fluoro-N’-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (II.d)

Intermediate 2c was deprotected under the reported acidic conditions (TFA) to afford, after an aqueous workup with NaHCO3 and extractions with EtOAc, a white solid, which was engaged without further purification for the next step. White solid (23 mg, 24% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.31 (s, 1H), 8.64 (s, 0.5H), 8.54–7.71 (m, 6.5H), 7.59–7.14 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 162.02, 160.08, 158.80, 150.13, 145.75, 144,71, 144.62, 141.43, 141.34, 140.47, 137.50, 137.04, 136.76, 136.33, 135.04, 132.22, 129.70, 127.83, 127.28, 127.20, 127.15, 127.07, 126.16, 125.03, 123.37, 120.85, 120.60, 118.72, 114.78, 114.43, 114.24, 114.01, 113.82, 109.37, 109.16, 108.79, 108.59; HRMS (ESI) m/z: calcd. for C15H11FN3OS [M + H]+ 300.0601, found 300.0603.

(E)-N’-((1H-Imidazol-4-yl)methylene)-6-chlorobenzo[b]thiophene-2-carbohydrazide (III.a)

Intermediate 2b was deprotected under the reported acidic conditions (TFA) to afford, after an aqueous workup with NaHCO3 and extractions with EtOAc, a white solid, which was engaged without further purification for the next step. Beige powder (90 mg, 48% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.92 (s, 0.5H), 12.52 (s, 0.5H), 11.92 (s, 0.5H), 11.85 (s, 0.5H), 8.53–8.35 (m, 1H), 8.31–8.13 (m, 1.5H), 8.13–7.96 (m, 1.5H), 7.90–7.67 (m, 1.5H), 7.67–7.40 (m, 1.5H); 13C NMR (101 MHz, DMSO-d6) δ 157.66, 144.16, 141.51, 139.58, 137.86, 136.71, 131.38, 130.92, 126.77, 125.75, 125.34, 124.90, 122.48, 122.08; MS (ESI) m/z = 305.1 [M + H]+, 327.0 [M + Na]+.

(E)-6-Chloro-N’-(furan-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (III.b)

Intermediate 2b was deprotected under the reported acidic conditions (TFA) to afford a white solid, which was engaged without further purification for the next step. Beige powder (145 mg, 78% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.12 (s, 0.5H), 12.04 (s, 0.5H), 8.43 (s, 0.5H), 8.34 (s, 0.5H), 8.30–8.12 (m, 1.5H), 8.12–7.96 (m, 1.5H), 7.88 (s, 1H), 7.57–7.41 (m, 1H), 7.06 (s, 0.5H), 6.99 (s, 0.5H), 6.67 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 158.34, 149.66, 145.94, 142.04, 139.68, 138.42, 138.25, 135.33, 134.70, 131.97, 131.65, 127.49, 127.30, 126.24, 125.90, 125.64, 122.96, 122.56, 114.70, 114.23, 112.79; MS (ESI) m/z = 305.0 [M + H]+, 327.0 [M + Na]+.

(E)-6-Chloro-N’-((5-(hydroxymethyl)furan-2-yl)methylene)benzo[b]thiophene-2-carbohydrazide (III.c)

Intermediate 2b was deprotected under the reported acidic conditions (TFA) to afford a white solid, which was engaged without further purification for the next step. Beige powder (94 mg, 46% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.09 (s, 0.5H), 12.03 (s, 0.5H), 8.44 (s, 0.5H), 8.36–8.15 (m, 2H), 8.12–7.94 (m, 1.5H), 7.50 (d, J = 8.4 Hz, 1H), 7.15–6.85 (m, 1H), 6.47 (s, 1H), 5.44 (t, J = 6.3 Hz, 1H), 4.63–4.29 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 158.22, 157.89, 148.44, 141.61, 139.28, 137.89, 136.46, 135.18, 134.30, 131.54, 131.16, 127.07, 126.86, 125.82, 125.45, 125.19, 122.51, 122.11, 115.54, 114.25, 109.38, 55.82; MS (ESI) m/z = 335.0 [M + H]+, 357.0 [M + Na]+.

(E)-6-Chloro-N’-(pyridin-2-ylmethylene)benzofuran-2-carbohydrazide (III.e)

Intermediate 2e was deprotected under the reported acidic conditions (TFA) to afford, after an aqueous workup with NaHCO3 and extractions with EtOAc, a white solid, which was engaged without further purification for the next step. White powder (63 mg, 44% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.45 (s, 1H), 8.63 (dd, J = 4.8, 1.5 Hz, 1H), 8.54 (s, 1H), 8.03–7.73 (m, 5H), 7.49–7.41 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 154.59, 153.05, 149.11, 148.57, 137.00, 131.93, 126.04, 124.67, 124.27, 120.17, 112.29, 111.20; HRMS (ESI) m/z: calcd. for C15H11ClN3O2 [M + H]+ 300.0534, found 300.0533.

(E)-N’-(Pyridin-2-ylmethylene)-6-(trifluoromethyl)benzo[b]thiophene-2-carbohydrazide (III.f)

Intermediate 2d was deprotected under the reported acidic conditions (TFA) to afford, after an aqueous workup with NaHCO3 and extractions with EtOAc, a white solid, which was engaged without further purification for the next step. White powder (64 mg, 44% yield). 1H NMR (300 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.70–8.59 (m, 2H), 8.52 (d, J = 13.4 Hz, 1H), 8.39–8.18 (m, 3H), 8.07–7.85 (m, 2H), 7.77 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 6.5 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 161.37, 158.04, 152.99, 152.78, 149.68, 148.84, 145.64, 142.91, 141.86, 141.72, 140.29, 139.92, 137.13, 137.02, 136.72, 131.50, 126.66, 126.51, 125.55, 124.69, 124.61, 121.45, 121.09, 120.88, 120.83, 120.77, 120.71, 120.68, 120.59, 120.19; HRMS (ESI) m/z: calcd. for C16H11F3N3OS [M + H]+ 350.0569, found 350.0572.

2.1.8. Procedure for N’-(Pyridin-2-ylmethyl)benzo[b]thiophene-2-carbohydrazide (I.p)

Under H2 atmosphere, a solution of (E)-N’-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (0.12 mmol, 1 eq.) and palladium on carbon 10% (0.019 mmol, 15 mol%) in 5 mL of EtOAc and 1 mL of MeOH was stirred at room temperature for 7 h. The mixture was filtered on Celite® and washed with EtOAc, and the residue was concentrated under vacuum and purified by chromatography (eluent: EtOAc/MeOH 98:2). (Adapted from Kim et al. [22]).

N’-(Pyridin-2-ylmethyl)benzo[b]thiophene-2-carbohydrazide (I.p)

White powder (30 mg, 60% yield). 1H NMR (300 MHz, DMSO-d6) δ 10.34 (d, J = 5.1 Hz, 1H), 8.63–8.40 (m, 1H), 8.04–7.98 (m, 2H), 7.95–7.88 (m, 1H), 7.78 (td, J = 7.7, 1.8 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.49–7.38 (m, 2H), 7.32–7.21 (m, 1H), 5.76 (q, J = 5.1 Hz, 1H), 4.12 (d, J = 5.1 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 161.02, 158.23, 148.90, 140.04, 139.12, 138.16, 136.59, 126.25, 125.20, 125.00, 124.69, 122.82, 122.36, 122.32, 56.21; HRMS (ESI) m/z: calcd. for C15H14N3OS [M + H]+ 284.0852, found 284.0858.

2.1.9. Procedure for Pyridine 2-aldoxime (6)

To a solution of pyridine-2-carboxaldehyde (1.87 mmol, 1 eq.) and hydroxylamine hydrochloride (2.33 mmol, 1.25 eq.) in water (5 mL) was added dropwise a solution of sodium bicarbonate (2.33 mmol, 1.25 eq.) in water (10 mL), and the mixture was stirred for 3 h at room temperature. The solution was then extracted with EtOAc and the organic layer dried over Na2SO4 and concentrated under vacuum. (Adapted from Younus Wani et al. 2011 ([23]).

Pyridine 2-aldoxime (6)

White powder (186 mg, 81%). 1H NMR (300 MHz, Chloroform-d) δ 8.99 (s, 1H), 8.63 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 8.31 (s, 1H), 7.82 (dt, J = 8.1, 1.0 Hz, 1H), 7.72 (td, J = 8.1, 1.8 Hz, 1H), 7.29 (ddd, J = 8.1, 4.9, 1.0 Hz, 1H). (Spectrum in accordance with Zhang et al. [24]).

2.1.10. Procedure for (E)-Picolinaldehyde O-(6-chlorobenzo[b]thiophene-2-carbonyl) oxime (III.d)

Under a dried and inert atmosphere (N2), a solution of 6-chlorobenzothiophene-2-carboxylic acid (1.06 mmol, 1.3 eq.) and pyridine 2-aldoxime (0.82 mmol, 1.0 eq.) in anhydrous DCM (3 mL) was cooled to 0 °C. Then, DMAP (0.12 mmol, 0.15 eq.) and DCC (1.06 mmol, 1.3 eq.) were gradually added to the mixture. The mixture was stirred at room temperature overnight and then filtered on Celite® and washed with DCM. The filtrate was then concentrated, and the residue was purified by column chromatography (eluent: pentane/EtOAc 2:1).

(E)-Picolinaldehyde O-(6-chlorobenzo[b]thiophene-2-carbonyl) oxime (III.d)

Orange powder (166 mg, 64% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.77–8.73 (m, 1H), 8.43 (d, J = 0.7 Hz, 1H), 8.33 (dt, J = 1.9, 0.7 Hz, 1H), 8.10 (dd, J = 8.5, 0.7 Hz, 1H), 8.04–7.95 (m, 2H), 7.62–7.54 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 159.04, 158.37, 150.12, 148.94, 142.67, 137.31, 137.04, 132.61, 131.55, 131.02, 127.37 (2C), 126.05, 122.57, 122.49; HRMS (ESI) m/z: calcd. for C15H10ClN2O2S [M + H]+ 317.0146, found 317.0136.

2.2. Biological Assays

2.2.1. Minimum Inhibitory Concentration (MIC) Evaluation

MICs were evaluated in CaMHB (cation-adjusted Mueller–Hinton broth) by the method of microdilution in liquid medium, which follows the CLSI recommendations (Clinical and Laboratory Standards Institute (CLSI), methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard seventh edition. Clinical and Laboratory Standards Institute, Wayne, PA, USA). Evaluated compounds were diluted in DMSO with a concentration of 5 mg/mL and then further diluted in CaMHB. The 0.5 MacFarland bacterial suspensions were made from colonies previously grown on blood agar plate (COS, Biomérieux) in a saline solution (0.45% NaCl). They were diluted in CaMHB (1/100) before addition into 96-well microplates. MICs were carried out in triplicate and determined after 18 h of incubation at 37 °C. The median values were reported.

2.2.2. Cytotoxicity Assay

Cytotoxicity was evaluated using a propidium iodide assay. Briefly, human lung adenocarcinomic A549 cells were plated on black flat 96-well plates (Greiner) at a concentration of 0.5 × 106 cells/mL in DMEM GlutaMAX (Gibco) supplemented with 10% fetal bovine serum for 24 h in a humidified atmosphere at 37 °C and 5% CO2. The medium was then removed and fresh medium with 2.5 µg/mL of propidium iodide and tested compounds (128 µg/mL of II.b and 0.2 µg/mL for recombinant Hla) was added. Absorbance at 618 nm was measured every 10 min over 7 h. Each concentration was made in triplicate and mean values are displayed with standard deviation.

3. Results and Discussion

3.1. Synthesis and Biological Evaluation of Series I—Benzo[b]thiophene-2-Acylhydrazones

Benzo[b]thiophene-2-acylhydrazones I derived from various aldehydes were first investigated (Figure 1).
The synthetic route to these compounds was achieved by the conversion of benzothiophene-2-carboxylic acid 1a into tert-butyl 2-(benzothiophene-2-carbonyl)hydrazinecarboxylate 2a in 88% yield using DCC as a coupling reagent. This method was preferred to the substitution of methyl benzothiophene-2-carboxylate with hydrazine, leading to a mixture of products difficult to purify [25]. Then, the tert-butyl carboxylate group was removed under acidic conditions using TFA to give a crude material which was then engaged without purification for reaction with diversely substituted aromatic or heteroaromatic aldehydes under acidic and refluxing conditions to form the imine bond of the acylhydrazone (Scheme 1).
All the synthesized derivatives I were conveniently obtained in satisfactory yields by spontaneous precipitation in pure form in the reaction medium after two hours of reflux. Compounds such as the 2-pyridinyl derivative I.c required the careful removal of all traces of acid after TFA deprotection, by a basic aqueous work-up and extraction with ethyl acetate before reaction with 2-pyridinecarboxaldehyde.
Structural analysis showed the presence of mixtures of geometric isomers for each final compound, as 1H and 13C NMR signals were split in two (spectra available in Supplementary Materials, Figure S1). Theoretically, each N-acylhydrazone derivative could present four different isomers due to (E)/(Z) and s-cis/s-trans isomerism. Previous studies have shown that only the more stable (E)-isomer is generated due to the steric hindrance and under such thermodynamic conditions, and that s-cis- and s-trans-isomers (rotamers) were identified by 1H NMR spectroscopy [13,26,27]. To demonstrate the presence of rotamers in the case of the piperonyl derivative I.a, the temperature of 1H NMR experiments was gradually increased, and the expected coalescence phenomenon was observed at 330 K and at higher temperatures (Figure 2).
This first set of compounds was then tested on three strains of Staphylococcus aureus, including a reference (ATCC29213) and two clinically isolated strains, resistant to methicillin (SF8300) and daptomycin (ST20171643), respectively. The purpose of this experiment was to establish the minimum inhibitory concentration (MIC), which is the minimum concentration of compound needed to prevent the growth of a standardized bacterial inoculum, for the benzo[b]thiophene-derived acylhydrazones. The results are presented in Table 1.
In this series, the two most active compounds are the piperonyl derivative I.a, which shows a MIC of 32 µg/mL for ATCC29213 and a range from 16 to 64 µg/mL for the two strains of antibiotic-resistant S. aureus, and the pyridinyl compound I.c, which shows a MIC of 16 µg/mL for every strain tested, making it the most potent molecule in this series. Interestingly, the position of the nitrogen atom in position 2 of the pyridine moiety in I.c was found to be important, as the other pyridinyl compounds I.d and I.e, in which the nitrogen is, respectively, in position 3 and 4, were found to be inactive. In this set, another position of interest in the phenyl ring is position 4 (I.i, I.l and, to a lesser extent, I.a), with interesting MICs for the products, while the others had no biological activity.
To examine the effect of the reduction of the imine bond and its consequences on free rotation and conjugation, the pyridinyl compound I.c was reduced using palladium over carbon under a H2 atmosphere with a 60% yield (Scheme 2). Reduced compound I.p exhibited a MIC four times higher than the one of I.c (Table 1). It is therefore suggested that preventing the free rotation of the pyridine ring and allowing conjugation due to the tautomeric form of the amide bond is important for the activity of I.c. An effect of hydrophobicity is also observed, decreasing the LogP from 3.13 for I.c to 2.33 for I.p.

3.2. Synthesis and Biological Evaluation of Series II—6-Halogenobenzo[b]thiophene-2-Acylhydrazones

Based on this first set of results, we selected the two compounds I.a and I.c (bearing a 5-piperonyl and a 2-pyridinyl moiety, respectively) as hits for further structural modulation. With 6-halogenobenzo[b]thiophene rings, being easily accessible using 2-fluoro-4-halogenobenzaldehyde as precursor, we prepared a series of four compounds, namely two piperonyl or pyridinyl compounds bearing a fluorine or chlorine atom, respectively (Figure 3).
In order to synthesize the acylhydrazones, 6-chloro- and 6-fluorobenzo[b]thiophene-2-carboxylic acids 1b and 1c were thus prepared. First, 2-fluoro-4-halogenobenzaldehyde reacted with ethyl thioglycolate by nucleophilic substitution followed by an intramolecular cyclization to obtain compounds 4a and 4b, as described in the literature [14]. These esters were then saponified with sodium hydroxide to give the desired carboxylic acids 1b and 1c. The general procedure used for the first set was applied to the latter to obtain compounds II.ad with similar yields, as shown in Scheme 3.
These compounds were also tested to establish their MIC against S. aureus with the same method used for set I, and the results are presented in Table 2.
This short series allowed us to identify the chloropyridinyl compound II.b as significantly more active compared with its non-halogenated counterpart I.c, reaching 4 µg/mL for the three strains. The presence of a fluorine atom in position 6 of the benzothiophene for the pyridinyl compound did not change the activity. Both halogenated compounds derived from the piperonyl compound I.a were deprived of biological activity (II.a and II.c).

3.3. Synthesis and Biological Evaluation of Series III—Structural Modifications of II.b

Attempts to improve the activity of the chloropyridinyl compound II.b were then undertaken by replacing the pyridine ring with three five-bond rings, namely imidazole, furan and 5-hydroxymethylfuran. The procedure used was the same as the one used for chlorinated derivatives II.a and II.b (Scheme 3). As shown in Table 3, the activity remains better for compound II.b, confirming the importance of the 2-pyridinyl group.
Then, the acylhydrazone was replaced by an acyloxime moiety, leading to a more flexible molecule and losing the s-cis/s-trans isomerism. Compound III.d was obtained through the conversion of pyridine-2-carboxaldehyde into the corresponding oxime 6, followed by the acylation from 6-chlorobenzo[b]thiophene-2-carboxylic acid 1b (Scheme 4).
Compound III.d showed no anti-staphylococcal activity at concentrations lower or equal to 256 µg/mL (Table 3). Therefore, the rigidity imposed by the acylhydrazone moiety is critical to the biological activity.
Then, the effect of the hydrophobicity of the compounds on the antibacterial activity was investigated using the benzo[b]furan counterpart of II.b (Scheme 5). First, 4-chloro-2-hydroxybenzaldehyde 3d was converted into the ester 4d using diethyl 2-bromomalonate as described [18]. Then, the synthetic route was the same as described before for benzo[b]thiophene acylhydrazone derivatives.
As shown in Table 3, compound III.e showed a weak activity against S. aureus with MIC values ≥ 128 µg/mL. Therefore, the hydrophobicity of the benzo[b]thiophene ring is critical for the biological activity. As expected, the replacement of the sulfur by an oxygen atom decreases the overall LogP of the compound (3.79 for II.b and 3.15 for III.e).
Finally, the chlorine atom was replaced by a bioisostere, a trifluoromethyl group, using the same synthetic strategy (Scheme 3), leading to compound III.f. Even if the MICs are interesting (Table 3), the chlorinated derivative II.b remains the most active compound.

3.4. Cytotoxicity Assay of II.b

Due to its interesting antistaphylococcal activity, the potential mammalian cytotoxicity of the chloropyridinyl derivative II.b was examined. Therefore, a 7 h propidium iodide (PI)-based assay was used on adenocarcinomic human alveolar basal epithelial cells (A549), with recombinant S. aureus α-hemolysin as a positive control. As depicted in Figure 4, no cytotoxicity was found for II.b after 7 h at a concentration of 128 µg/mL (32 times the MIC).

4. Conclusions

In this study, benzo[b]thiophene-based acylhydrazones were shown to be interesting compounds acting as anti-staphylococcal agents. More precisely, (E)-6-chloro-N’-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide II.b showed an equal minimum inhibitory concentration of 4 µg/mL for the three strains of S. aureus, including two clinically isolated strains of drug-resistant S. aureus. Moreover, II.b showing no cytotoxicity on A549 cells; this suggests that the chloropyridinyl benzothiophene acylhydrazone structure is pertinent for future work on chemical diversification and the understanding of the mode of action.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/biom12010131/s1, Figure S1: 1H- and 13C-NMR spectra for new compounds.

Author Contributions

Conceptualization, Y.Q., O.D., G.L. and L.S.; methodology, T.B., A.B. (Alexia Barbry), J.M., C.B., F.D. and A.B. (Anne Baudouin); writing—original draft preparation, T.B., J.M., Y.Q. and L.S.; writing—review and editing, T.B., A.B. (Alexia Barbry), J.M., C.B., F.D, A.B. (Anne Baudouin), Y.Q., O.D., G.L. and L.S.; supervision, C.B., Y.Q., O.D., G.L. and L.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no specific funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data can be found in the manuscript and in the Supplementary Materials.

Acknowledgments

Financial support from MESRI, CNRS and INSERM is gratefully acknowledged. Thibaut Barbier thanks MESRI, France for a scholarship.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bradley, J.S.; Guidos, R.; Baragona, S.; Bartlett, J.G.; Rubinstein, E.; Zhanel, G.G.; Tino, M.D.; Pompliano, D.L.; Tally, F.; Tipirneni, P.; et al. Anti-infective research and development--problems, challenges, and solutions. Lancet Infect. Dis. 2007, 7, 68–78. [Google Scholar] [CrossRef]
  2. Spellberg, B.; Powers, J.H.; Brass, E.P.; Miller, L.G.; Edwards, J.E., Jr. Trends in antimicrobial drug development: Implications for the future. Clin. Infect. Dis. 2004, 38, 1279–1286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Neill, J.O. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. In Review Paper-Tackling a Crisis for the Health and Wealth of Nations; HM Government Wellcome Trust: London, UK, 2014; pp. 1–20. [Google Scholar]
  4. Rasko, D.A.; Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 2010, 9, 117–128. [Google Scholar] [CrossRef]
  5. Keri, R.S.; Chand, K.; Budagumpi, S.; Balappa Somappa, S.; Patil, S.A.; Nagaraja, B.M. An overview of benzo[b]thiophene-based medicinal chemistry. Eur. J. Med. Chem. 2017, 138, 1002–1033. [Google Scholar] [CrossRef]
  6. Hadda, T.B.; Srivastava, S.; Das, B.; Salgado-Zamora, H.; Shaheen, U.; Bader, A.; Naseer, M.M. POM analyses of antimicrobial activity of some 2,3-armed 4,5,6,7-tetrahydro-1-benzothiophenes: Favourable and unfavourable physico-chemical parameters in design of antibacterial and mycolytic agents. Med. Chem. Res. 2014, 23, 995–1003. [Google Scholar] [CrossRef]
  7. Kumara, T.H.S.; Mahadevan, K.M.; Harishkumar, H.N.; Padmashali, B.; Naganagowda, G. Synthesis of Benzo[b]thiophene Substituted Carbamates, Ureas, Semicarbazides, and Pyrazoles and Their Antimicrobial and Analgesic Activity. Phosphorus Sulfur Silicon Relat. Elem. 2009, 184, 1866–1879. [Google Scholar] [CrossRef]
  8. Penthala, N.R.; Sonar, V.N.; Horn, J.; Leggas, M.; Yadlapalli, J.S.; Crooks, P.A. Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents. Medchemcomm 2013, 4, 1073–1078. [Google Scholar] [CrossRef] [Green Version]
  9. Moinet, G.; Leriche, C.; Kergoat, M. Antidiabetic Compounds Comprising Benzofuran and Benzothiophene Derivatives. U.S. Patent 7375130B2, 20 May 2008. [Google Scholar]
  10. Berrade, L.; Aisa, B.; Ramirez, M.J.; Galiano, S.; Guccione, S.; Moltzau, L.R.; Levy, F.O.; Nicoletti, F.; Battaglia, G.; Molinaro, G.; et al. Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action. J. Med. Chem. 2011, 54, 3086–3090. [Google Scholar] [CrossRef]
  11. Fakhr, I.M.; Radwan, M.A.; el-Batran, S.; Abd el-Salam, O.M.; el-Shenawy, S.M. Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents. Eur. J. Med. Chem. 2009, 44, 1718–1725. [Google Scholar] [CrossRef]
  12. Pathak, C.; Ranjan Singh, R.; Yadav, S.; Kapoor, N.; Raina, V.; Gupta, S.; Surolia, A. Evaluation of benzothiophene carboxamides as analgesics and anti-inflammatory agents. IUBMB Life 2014, 66, 201–211. [Google Scholar] [CrossRef]
  13. Thota, S.; Rodrigues, D.A.; Pinheiro, P.S.M.; Lima, L.M.; Fraga, C.A.M.; Barreiro, E.J. N-Acylhydrazones as drugs. Bioorg. Med. Chem. Lett. 2018, 28, 2797–2806. [Google Scholar] [CrossRef]
  14. Fedi, V.; Altamura, M.; Catalioto, R.M.; Giannotti, D.; Giolitti, A.; Giuliani, S.; Guidi, A.; Harmat, N.J.; Lecci, A.; Meini, S.; et al. Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J. Med. Chem. 2007, 50, 4793–4807. [Google Scholar] [CrossRef]
  15. Mueller, C.E.; Pegurier, C.; Deligny, M.L.R.; El-Tayeb, A.; Hockemeyer, J.; Ledecq, M.; Mercier, J.; Provins, L.; Boshta, N.M.; Bhattarai, S. (aza) indole-, benzothiophene-, and benzofuran-3-sulfonamides. WO Patent 2018122232, 5 July 2018. [Google Scholar]
  16. Cheng, K.; Wang, X.; Yin, H. Small-molecule inhibitors of the TLR3/dsRNA complex. J. Am. Chem. Soc. 2011, 133, 3764–3767. [Google Scholar] [CrossRef] [Green Version]
  17. Tan, Y.J.; Li, M.; Gunawan, G.A.; Nyantakyi, S.A.; Dick, T.; Go, M.L.; Lam, Y. Amide-Amine Replacement in Indole-2-carboxamides Yields Potent Mycobactericidal Agents with Improved Water Solubility. ACS Med. Chem. Lett. 2021, 12, 704–712. [Google Scholar] [CrossRef]
  18. Li, Z.; Xu, Q.; Yu, C.; Yee, C.; Gwaltney, I.S.L.; Metcalf, B.W.; Richards, S.; Lardy, M.A.; Setti, L.; Sham, H. Pyrazolopyridine Pyrazolopyrimidine and Related Compounds. U.S. Patent 2015315198, 5 November 2015. [Google Scholar]
  19. Chen, W.; Zhou, Z.H.; Chen, H.B. Efficient synthesis of chiral benzofuryl β-amino alcohols via a catalytic asymmetric Henry reaction. Org. Biomol. Chem. 2017, 15, 1530–1536. [Google Scholar] [CrossRef] [PubMed]
  20. Cai, G.; Yu, W.; Song, D.; Zhang, W.; Guo, J.; Zhu, J.; Ren, Y.; Kong, L. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors. Eur. J. Med. Chem. 2019, 174, 236–251. [Google Scholar] [CrossRef]
  21. Gensini, M.; Altamura, M.; Dimoulas, T.; Fedi, V.; Giannotti, D.; Giuliani, S.; Guidi, A.; Harmat, N.J.; Meini, S.; Nannicini, R.; et al. Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK(2) receptor antagonists. ChemMedChem 2010, 5, 65–78. [Google Scholar] [CrossRef]
  22. Kim, B.K.; Ko, H.; Jeon, E.S.; Ju, E.S.; Jeong, L.S.; Kim, Y.C. 2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors. Eur. J. Med. Chem. 2016, 120, 202–216. [Google Scholar] [CrossRef] [PubMed]
  23. Younus Wani, M.; Athar, F.; Salauddin, A.; Mohan Agarwal, S.; Azam, A.; Choi, I.; Roouf Bhat, A. Novel terpene based 1,4,2-dioxazoles: Synthesis, characterization, molecular properties and screening against Entamoeba histolytica. Eur. J. Med. Chem. 2011, 46, 4742–4752. [Google Scholar] [CrossRef] [PubMed]
  24. Zhang, X.-P.; Liu, J.; Zhang, J.-X.; Huang, J.-H.; Wan, C.-Z.; Li, C.-H.; You, X.-Z. Synthesis and ferroelectric properties of platinum (II) complexes with chiral isoxazoline ligand. Polyhedron 2013, 60, 85–92. [Google Scholar] [CrossRef]
  25. Leonczak, P.; Gao, L.J.; Ramadori, A.T.; Lescrinier, E.; Rozenski, J.; De Jonghe, S.; Herdewijn, P. Synthesis and structure-activity relationship studies of 2-(1,3,4-oxadiazole-2(3H)-thione)-3-amino-5-arylthieno [2,3-b]pyridines as inhibitors of DRAK2. ChemMedChem 2014, 9, 2587–2601. [Google Scholar] [CrossRef] [PubMed]
  26. Palla, G.; Predieri, G.; Domiano, P.; Vignali, C.; Turner, W. Conformational behaviour and E/Z isomerization of N-acyl and N-aroylhydrazones. Tetrahedron 1986, 42, 3649–3654. [Google Scholar] [CrossRef]
  27. Kumar, P.; Kadyan, K.; Duhan, M.; Sindhu, J.; Singh, V.; Saharan, B.S. Design, synthesis, conformational and molecular docking study of some novel acyl hydrazone based molecular hybrids as antimalarial and antimicrobial agents. Chem. Cent. J. 2017, 11, 115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Figure 1. General structure of set I derivatives.
Figure 1. General structure of set I derivatives.
Biomolecules 12 00131 g001
Scheme 1. Synthesis of set I derivatives.
Scheme 1. Synthesis of set I derivatives.
Biomolecules 12 00131 sch001
Figure 2. 1H NMR spectra of I.a at different temperatures.
Figure 2. 1H NMR spectra of I.a at different temperatures.
Biomolecules 12 00131 g002aBiomolecules 12 00131 g002b
Scheme 2. Synthesis of compound I.p.
Scheme 2. Synthesis of compound I.p.
Biomolecules 12 00131 sch002
Figure 3. General structure of set II derivatives.
Figure 3. General structure of set II derivatives.
Biomolecules 12 00131 g003
Scheme 3. Synthesis of set II and III derivatives.
Scheme 3. Synthesis of set II and III derivatives.
Biomolecules 12 00131 sch003
Scheme 4. Synthesis of III.d.
Scheme 4. Synthesis of III.d.
Biomolecules 12 00131 sch004
Scheme 5. Synthesis of III.e.
Scheme 5. Synthesis of III.e.
Biomolecules 12 00131 sch005
Figure 4. Effect of II.b on the growth of A549 cells.
Figure 4. Effect of II.b on the growth of A549 cells.
Biomolecules 12 00131 g004
Table 1. Minimum inhibitory concentrations of set I molecules against S. aureus strains.
Table 1. Minimum inhibitory concentrations of set I molecules against S. aureus strains.
NameStructureLogPMIC (µg/mL)
ATCC 29213 aSF8300 bST20171643 c
I.a Biomolecules 12 00131 i0014.20326416
I.b Biomolecules 12 00131 i0024.41>256>256>256
I.c Biomolecules 12 00131 i0033.13161616
I.d Biomolecules 12 00131 i0043.07>256>256>256
I.e Biomolecules 12 00131 i0053.02>256>256>256
I.f Biomolecules 12 00131 i0063.80>256>256ND
I.g Biomolecules 12 00131 i0073.83>256>256>256
I.h Biomolecules 12 00131 i0083.64>256>256>256
I.i Biomolecules 12 00131 i0094.98128128128
I.j Biomolecules 12 00131 i0104.47>256>256128
I.k Biomolecules 12 00131 i0114.24>256>256ND
I.l Biomolecules 12 00131 i0124.26646432
I.m Biomolecules 12 00131 i0133.83256>256>256
I.n Biomolecules 12 00131 i0144.19>256>256256
I.o Biomolecules 12 00131 i0154.22>256>256256
I.p Biomolecules 12 00131 i0162.33646464
a: methicillin-sensitive S. aureus; b: methicillin-resistant S. aureus; c: daptomycin-resistant S. aureus.
Table 2. Minimum inhibitory concentrations of set II molecules against S. aureus strains.
Table 2. Minimum inhibitory concentrations of set II molecules against S. aureus strains.
NameStructureLogPMIC (µg/mL)
ATCC 29213 aSF8300 bST20171643 c
II.a Biomolecules 12 00131 i0174.85>256>256>256
II.b Biomolecules 12 00131 i0183.79444
II.c Biomolecules 12 00131 i0194.33>256>256>256
II.d Biomolecules 12 00131 i0203.27321616
a: methicillin-sensitive S. aureus; b: methicillin-resistant S. aureus; c: daptomycin-resistant S. aureus.
Table 3. Minimum inhibitory concentrations of set III molecules against S. aureus strains.
Table 3. Minimum inhibitory concentrations of set III molecules against S. aureus strains.
NameStructureLogPMIC (µg/mL)
ATCC 29213 aSF8300 bST20171643 c
III.a Biomolecules 12 00131 i0213.192566464
III.b Biomolecules 12 00131 i0224.22>256256256
III.c Biomolecules 12 00131 i0233.79>256256256
III.d Biomolecules 12 00131 i0243.89>256>256>256
III.e Biomolecules 12 00131 i0253.15>256256128
III.f Biomolecules 12 00131 i0264.0132816
a: methicillin-sensitive S. aureus; b: methicillin-resistant S. aureus; c: daptomycin-resistant S. aureus.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Barbier, T.; Barbry, A.; Magand, J.; Badiou, C.; Davy, F.; Baudouin, A.; Queneau, Y.; Dumitrescu, O.; Lina, G.; Soulère, L. Synthesis and Biological Evaluation of Benzo[b]thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant Staphylococcus aureus. Biomolecules 2022, 12, 131. https://doi.org/10.3390/biom12010131

AMA Style

Barbier T, Barbry A, Magand J, Badiou C, Davy F, Baudouin A, Queneau Y, Dumitrescu O, Lina G, Soulère L. Synthesis and Biological Evaluation of Benzo[b]thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant Staphylococcus aureus. Biomolecules. 2022; 12(1):131. https://doi.org/10.3390/biom12010131

Chicago/Turabian Style

Barbier, Thibaut, Alexia Barbry, Jérémy Magand, Cédric Badiou, Floriane Davy, Anne Baudouin, Yves Queneau, Oana Dumitrescu, Gérard Lina, and Laurent Soulère. 2022. "Synthesis and Biological Evaluation of Benzo[b]thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant Staphylococcus aureus" Biomolecules 12, no. 1: 131. https://doi.org/10.3390/biom12010131

APA Style

Barbier, T., Barbry, A., Magand, J., Badiou, C., Davy, F., Baudouin, A., Queneau, Y., Dumitrescu, O., Lina, G., & Soulère, L. (2022). Synthesis and Biological Evaluation of Benzo[b]thiophene Acylhydrazones as Antimicrobial Agents against Multidrug-Resistant Staphylococcus aureus. Biomolecules, 12(1), 131. https://doi.org/10.3390/biom12010131

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop